A combination of radiation therapy and hormone treatment can cut by 43 percent the risk of death in men suffering from locally advanced or high-risk prostate cancer, a study unveiled here Sunday showed.
The research presented at the annual American Society of Clinical Oncology conference showed that adding radiation therapy to androgen deprivation therapy (ADT) produced significant benefits for the cancer patients.
"This study will challenge the prevailing dogma of using hormone therapy for locally advanced prostate cancer," said Padraig Warde, deputy head of the radiation medicine program at the University of Toronto's Princess Margaret Hospital.
Around 20 percent of men affected by prostate cancer suffer from the types targeted by the trial.
"These results suggest that adding radiation therapy to the treatment plan for these patients could become part of standard therapy and should be considered," Warde said.
Some doctors and researchers have advocated the use of radiation alongside ADT, but it had been unclear whether ADT produces equally beneficial effects used alone, and there were also concerns about whether the side effects associated with radiation could be avoided.
ADT, which works by reducing the levels of certain male hormones that promote cancer growth, is standard treatment for men whose prostate cancer has not responded to either radiation or surgery.
The study treated 602 patients with hormones alone, and gave a second group of 603 men both radiation and ADT.
After seven years, 74 percent of those who received the combination of both therapies were alive, while only 66 percent of the men who had ADT alone survived.
In the ADT group, 26 percent died from their cancer, compared to a mortality rate of just 10 percent in the group that had both treatments.
And those who had both ADT and radiation lived an average of six months longer than patients who had hormone therapy alone, the study found.
The researchers said they expected the trend would continue, and forecast fewer than 15 percent of those who received the combined therapies would die from their prostate cancer over 10 years, compared to 23 percent in the ADT group.
The median follow-up time in the trial was six years, and a total of 320 patients died during the study, 175 from the ADT group and 145 from the combined group.